Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ReNeuron Group plc
DescriptionNeural stem cells derived from ReNeuron's c-mycER technology
Molecular Target Not applicable
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationPeripheral vascular disease (PVD)
Indication DetailsTreat critical limb ischemia; Treat critical limb ischemia (CLI) associated with peripheral artery disease (PAD); Treat peripheral arterial disease (PAD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today